18F-C-SNAT4

The drug 18F-C-SNAT4 is an improved 18F-labeled caspase-sensitive nanoaggregation tracer developed for PET imaging of tumor response to therapies. It works through a mechanism of caspase-3 triggered nanoaggregation, which allows for the detection of apoptosis (programmed cell death) in tumors following treatment with chemotherapy or immunotherapy. ## Mechanism of Action 18F-C-SNAT4 functions by undergoing an intramolecular cyclization reaction after being cleaved by caspase-3/7, which are biomarkers of apoptosis. This caspase-3/7-dependent reaction leads to enhanced accumulation and retention of the 18F radioactivity in apoptotic tumor cells. The tracer selectively targets and binds to tumor-associated antigens on tumor cells, allowing for visualization of cell death processes via PET imaging. ## Clinical Development The tracer has shown promising results in preclinical studies, demonstrating its ability to: - Detect drug-induced cell death in both murine lymphoma and human non-small cell lung cancer (NSCLC) models - Monitor tumor response to both chemotherapy and immunotherapy in preclinical mouse models - Distinguish between drug-sensitive and drug-resistant tumors A clinical trial (NCT04017819) has been conducted to study the biodistribution and pharmacokinetics of 18F-C-SNAT4 in healthy volunteers and patients with lung cancer. The trial aimed to: - Determine the biodistribution of 18F-C-SNAT4 in healthy volunteers - Assess dosimetry and acute toxicity - Evaluate uptake differences between tumor and non-cancer tissue - Verify the safety profile of the radiotracer - Determine the time of maximal radiotracer uptake post-injection ## Advantages 18F-C-SNAT4 has demonstrated several advantages over other radiotracers: - Improved serum stability profiles compared to previous versions - Higher sensitivity and significance in detecting treatment response compared to established radiotracers like 18F-FDG, 99mTc-Annexin V, and 18F-ML-10 - Ability to provide quantitative measurement of tumor apoptosis independent of changes in blood flow This radiotracer represents a promising tool for non-invasive monitoring of tumor response to therapy, which could potentially help in early assessment of treatment efficacy and improve patient management in clinical settings.

Other names

[18F]C-SNAT4